The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 15, 2010
Filed:
Jun. 25, 2004
Richard Weber, San Francisco, CA (US);
Xiao Feng, Union City, CA (US);
Orit Foord, Foster City, CA (US);
Larry Green, San Francisco, CA (US);
Jean M. Gudas, Santa Monica, CA (US);
Bruce Keyt, Hillsborough, CA (US);
Ying Liu, Palo Alto, CA (US);
Palaniswami Rathanaswami, Vancouver, CA;
Robert Raya, Fremont, CA (US);
Xiao Dong Yang, Palo Alto, CA (US);
Jose Corvalan, Foster City, CA (US);
Ian Foltz, Burnaby, CA;
Xiao-chi Jia, Los Angeles, CA (US);
Jaspal S. Kang, Surrey, CA;
Chadwick T. King, Vancouver, CA;
Scott L. Klakamp, Fremont, CA (US);
Qiaojuan Jane Su, San Jose, CA (US);
Richard Weber, San Francisco, CA (US);
Xiao Feng, Union City, CA (US);
Orit Foord, Foster City, CA (US);
Larry Green, San Francisco, CA (US);
Jean M. Gudas, Santa Monica, CA (US);
Bruce Keyt, Hillsborough, CA (US);
Ying Liu, Palo Alto, CA (US);
Palaniswami Rathanaswami, Vancouver, CA;
Robert Raya, Fremont, CA (US);
Xiao Dong Yang, Palo Alto, CA (US);
Jose Corvalan, Foster City, CA (US);
Ian Foltz, Burnaby, CA;
Xiao-Chi Jia, Los Angeles, CA (US);
Jaspal S. Kang, Surrey, CA;
Chadwick T. King, Vancouver, CA;
Scott L. Klakamp, Fremont, CA (US);
Qiaojuan Jane Su, San Jose, CA (US);
Amgen Fremont Inc., Fremont, CA (US);
Abstract
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.